Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference
Liquidia (NASDAQ: LQDA) has announced that its CEO, Dr. Roger Jeffs, will present at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15, 2025, at 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
The event will feature a live, audio-only webcast accessible via the “Investors” page on Liquidia’s website at https://liquidia.com/investors/events-and-presentations. For those unable to attend live, a replay and transcript of the webcast will be archived on the company's website for at least 30 days.
Liquidia (NASDAQ: LQDA) ha annunciato che il suo CEO, Dr. Roger Jeffs, presenterà al 43° Congresso Annuale J.P. Morgan Healthcare. La presentazione è programmata per mercoledì 15 gennaio 2025, alle 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) presso il Westin St. Francis a San Francisco, California.
L'evento prevederà un webinar audio in diretta accessibile tramite la pagina “Investitori” sul sito di Liquidia all'indirizzo https://liquidia.com/investors/events-and-presentations. Per coloro che non possono partecipare live, un ripristino e trascrizione del webinar sarà archiviato sul sito web della società per almeno 30 giorni.
Liquidia (NASDAQ: LQDA) ha anunciado que su CEO, Dr. Roger Jeffs, presentará en la 43ª Conferencia Anual de J.P. Morgan sobre Salud. La presentación está programada para miércoles, 15 de enero de 2025, a las 9:45 a.m. Hora del Pacífico (12:45 p.m. Hora del Este) en el Westin St. Francis en San Francisco, California.
El evento contará con un webcast en vivo solo de audio accesible a través de la página “Inversores” en el sitio web de Liquidia en https://liquidia.com/investors/events-and-presentations. Para aquellos que no puedan asistir en vivo, un repetición y transcripción del webcast será archivada en el sitio web de la empresa por al menos 30 días.
Liquidia (NASDAQ: LQDA)는 CEO인 Dr. Roger Jeffs가 제43회 연례 J.P. Morgan 헬스케어 콘퍼런스에서 발표할 것이라고 발표했습니다. 발표는 2025년 1월 15일 수요일에 오전 9시 45분 태평양 표준시 (오후 12시 45분 동부 표준시) 동안 샌프란시스코, 캘리포니아에 있는 Westin St. Francis에서 진행될 예정입니다.
이번 행사에서는 오디오 전용 생중계가 제공되며, Liquidia 웹사이트의 “투자자” 페이지를 통해 액세스할 수 있습니다. https://liquidia.com/investors/events-and-presentations. 라이브 행사에 참석할 수 없는 분들을 위해, 웹캐스트의 재생 및 전사본은 회사 웹사이트에 최소 30일 동안 보관될 예정입니다.
Liquidia (NASDAQ: LQDA) a annoncé que son PDG, Dr. Roger Jeffs, présentera à la 43e Conférence Annuelle J.P. Morgan de la Santé. La présentation est prévue pour mercredi 15 janvier 2025, à 9h45 heure du Pacifique (12h45 heure de l'Est) à l'hôtel Westin St. Francis à San Francisco, Californie.
L'événement comportera un webinaire audio en direct accessible via la page
Liquidia (NASDAQ: LQDA) hat bekannt gegeben, dass der CEO, Dr. Roger Jeffs, auf der 43. Jahreskonferenz von J.P. Morgan im Gesundheitswesen präsentieren wird. Die Präsentation ist für Mittwoch, den 15. Januar 2025, um 9:45 Uhr Pazifischer Zeit (12:45 Uhr Ostzeit) im Westin St. Francis in San Francisco, Kalifornien angesetzt.
Die Veranstaltung wird einen live, nur Audio-Webcast beinhalten, der über die „Investoren“-Seite auf der Website von Liquidia unter https://liquidia.com/investors/events-and-presentations zugänglich ist. Für diejenigen, die nicht live teilnehmen können, wird eine Wiederholung und Transkription des Webcasts mindestens 30 Tage lang auf der Unternehmenswebsite archiviert.
- None.
- None.
MORRISVILLE, N.C., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, beginning at approximately 9:45 a.m. Pacific Time (12:45 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California.
Access to a live, audio-only webcast will be available on the “Investors” page of Liquidia’s website at https://liquidia.com/investors/events-and-presentations. A replay and transcript of the webcast will be archived on the company's website for at least 30 days.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company’s current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia’s lead candidate, YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.
Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4400
jason.adair@liquidia.com
Media:
Patrick Wallace
919.328.4383
patrick.wallace@liquidia.com
FAQ
When will Liquidia present at the J.P. Morgan Healthcare Conference?
Who will represent Liquidia at the 43rd Annual J.P. Morgan Healthcare Conference?
How can I access the live webcast of Liquidia 's presentation at the J.P. Morgan Healthcare Conference?
Where is the 43rd Annual J.P. Morgan Healthcare Conference being held?
Will there be a replay available for Liquidia 's presentation at the J.P. Morgan Healthcare Conference?
What is the stock symbol for Liquidia ?
